Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-fat Meal Effect on Pimicotinib PK
NCT06884072Phase 1Active, not recruiting
- Sponsor
- Abbisko Therapeutics
- Start
- Apr 2025
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of pimicotinib in tenosynovial giant cell tumor (TGCT) (2 arms), sponsored by Abbisko Therapeutics. Primary endpoints: Maximum Plasma Concentration, Area Under the Concentration-Time Curve From Time Zero to Infinity and 1 more. Started Apr 2025; status: active, not recruiting.
02
Drugs
pimicotinib
03
Conditions
tenosynovial giant cell tumor (TGCT)
Beyond the preview
Go deeper on NCT06884072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06884072.